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Abstract
Background: Multiple sclerosis (MS) is a, T cell-mediated autoimmune disease, the management of which remains
challenging. The recently described fusion protein, Fn14·TRAIL, combining the extracellular domain of Fn14 (capable
of blocking the pro-inflammatory TWEAK ligand) fused to the extracellular domain of the TRAIL ligand (capable of
sending apoptotic signals through its receptors on activated inflammatory cells) was designed to modulate the
immune system as an anti-inflammatory agent. The present study explores the efficacy of this purified protein as an
anti-inflammatory agent, using the animal model of MS - experimental autoimmune encephalomyelitis (EAE).
Methods: EAE was induced by myelin oligodendrocyte glycoprotein (MOG). Fn14·TRAIL or vehicle were injected
daily for 4 to 16 days, at different time points after disease induction. Animals were examined daily and evaluated
for EAE clinical signs. Lymphocytes were analyzed for ex vivo re-stimulation, cytokine secretion, transcription factor
expression and subtype cell analysis. Spinal cords were checked for inflammatory foci. The Mann- Whitney rank sum
test, Student’s t-test or ANOVA were used for statistical analysis.
Results: Significant improvement of EAE in the group treated with Fn14·TRAIL was noted from day 6 of disease
onset and lasted until the end of follow-up (day 40 from disease induction), even in animals treated for 4 days only.
Clinical improvement was linked to decreased lymphocyte infiltrates in the central nervous system (CNS) and to
decreased Th1 and Th17 responses and to increased number of T- regulatory in the treated mice. No liver or kidney
toxicity was evident. In vitro assays established the ability of Fn14·TRAIL to induce apoptosis of T cell lines
expressing TRAIL receptors and TWEAK.
Conclusions: In this study we established the potency of Fn14·TRAIL, a unique fusion protein combining two
potentially functional domains, in inhibiting the clinical course of EAE, even when given for a short time, without
apparent toxicity. These findings make Fn14·TRAIL a highly promising agent to be used for targeted amelioration of
neuro-inflammatory processes, as well as other autoimmune pathologies.
Introduction
Multiple sclerosis (MS) is an autoimmune disease in
which T cells are sensitized against myelin components
[1]. Upon entering the central nervous system (CNS),
these encephalitogenic T cells are activated by resident
antigen-presenting cells and initiate a cascade of inflam-
matory damage. The initial inflammatory phase is
followed by a phase of selective demyelination and,
finally neurodegeneration [2,3]. Today, MS management
consists of classical anti-inflammatory agents for acute
relapses, and immunosuppression or immunomodula-
tory drugs given as maintenance and aimed to prevent
relapses and slowing down of disability progression [4].
Experimental autoimmune encephalomyelitis (EAE) is
the animal model used to study human MS and for in-
vestigation of neuroinflammation and autoimmunity in
general. The inflammatory process involves the extrava-
sation of activated T cells through blood vessel walls and
the activation of CNS immunocompetent cells, which
accumulate at the inflammatory sites. The initial inflam-
matory phase is followed by demyelination and
neurodegeneration [4]. EAE is widely used for the study
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of the underlying pathology of MS, and it has also
proved effective in the development of new therapies [5].
Effective treatment should target the pathogenic,
myelin-specific T cells in conjunction with preventing
their trafficking to the target in the CNS.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), has been shown to play an important role in at-
tenuating disease severity in myelin oligodendrocyte
glycoprotein (MOG)-induced EAE. TRAIL was found to
inhibit the proliferation of encephalitogenic T cells in
EAE, while chronic TRAIL blockade by soluble TRAIL
receptor was found to exacerbate EAE and enhance
MOG-specific Th1 and Th2 responses [6]. When EAE
was induced by adoptive transfer of genetically modified
embryonic stem cell-derived dendritic cells (ES-DC) pre-
senting MOG and expressing TRAIL, the disease was less
severe than when it was induced by transferring ES-DC
presenting MOG but not expressing TRAIL [6]. Of note,
these adoptively transferred, genetically modified ES-DCs,
presenting both MOG and TRAIL, also protected mice
from developing EAE induced by myelin basic protein, the
protection mediated by Foxp3 regulatory T cells [7].
Another TNF family member that has gained attention
for its role in EAE is the TNF-related weak inducer of
apoptosis (TWEAK). It is a type II membrane protein
containing 249 amino acids. Although widely expressed at
the mRNA level [8,9], membrane-anchored TWEAK pro-
tein has been found consistently only in interferon-(IFN)
γ-activated monocytes [10]. The TWEAK receptor, fibro-
blast growth factor-inducible-14 (Fn14, TNFRSF12A), is a
type I transmembrane protein with 129 amino acids and
lacks a cytoplasmic death domain [11,12]. Fn14 protein
expression has been described in fibroblasts [11], endothe-
lial [13,14], glioma [15] and neuronal cells [16]. Function-
ally, TWEAK promotes angiogenesis [14,17], migration of
endothelial and glioma cells [12,15] and has pro-
inflammatory properties. TWEAK expression has been
shown to be upregulated in EAE, and transgenic mice
over-expressing soluble TWEAK in the liver displayed a
significant decline of the disease [18]. It has been sug-
gested that TWEAK, by acting at the endothelial blood–
brain barrier (BBB) or in the CNS, might promote
leukocyte migration into the CNS parenchyma, resulting
in exacerbation of the disease [13]. Importantly, blocking
the interaction between TWEAK and its receptor by neu-
tralizing Abs against either of them ameliorated clinical
signs of EAE in mice and rats [19].
Recently, a chimeric protein combining the ability to
interfere with both TRAIL signaling and the TWEAK
(Fn14 axis, Fn14·TRAIL) was described [20]. Continuous
Fn14•TRAIL expression in EAE mice by a transposon-
based eukaryotic expression vector decreased disease se-
verity. This was reflected by a decrease in clinical score,
disease incidence, and CNS inflammation.
In the present study we tested the efficacy of purified
Fn14·TRAIL protein injected subcutaneously (s.c.) in a
chronic EAE model induced by MOG35-55 in C57 bl/6
mice. Our results show that Fn14·TRAIL ameliorated
clinical and pathological parameters of EAE, reducing
CNS inflammation and encephalitogenic T-cell reactiv-
ity. Treatment affected Th1 and Th17 lineages and re-
duced the expression of CCR5 + cells.
Materials and methods
Protein production
Human Fn14·TRAIL was produced and purified by
Cobra Bio-manufacturing (Keele, UK). Chinese hamster
ovary (CHO) cells were stably transfected with a DNA
construct expressing the human Fn14·TRAIL gene
driven by the cytomegalovirus (CMV) promoter. A
stable cell clone was isolated and fermented in a serum-
free medium. Fn14•TRAIL was purified from the medium,
using chromatographic methods, to >95% purity and
stored at -80°C. The amino acid sequence of the
Fn14•TRAIL protein is as follows: MRALLARLLLCV
LVVSDSKG EQAPGTAPCSRGSSWSADLDKCM DCA
SCRARPHSDFCLGCAAA PPAPFRLLW RG PQ RVA
AHITGTR GRSNTLSSPN SKNEKALGRK INSWE
SSRSG HSFLSNLHLR NGELVIHEKG FYYIYSQTYF
RFQEEIKENT KNDKQMVQYI YKYTSYPDPI LLMK
SARNSC WSKDAEYGLY SIYQGGIFEL KENDRIFVSV
TNEHLIDMDH EASFFGAFLVG. The ITALIC sequence
represents the signal-peptide of the human urokinase pro-
tein, utilized to secrete Fn14·TRAIL from the cell, and is
removed from the mature protein. The amino acid se-
quence of the extracellular domain of human Fn14
(amino-acids 1 to 52 of the mature protein, marked in bold
letters) are directly linked to the extracellular domain of
human TRAIL (amino-acids 53 to 217 of the mature pro-
tein, non-bold letters).
Animals and disease induction
Female pathogen-free mice (7 to 8-weeks-old) were pur-
chased from Harlan Laboratories, Rehovot, Israel, and
housed in the animal facility of the Hebrew University
Medical School in accordance with the National Institute
of Health guidelines. All experiments were approved by
the Animal Care Committee of the Hebrew University.
EAE was induced as previously described please (21)
by injecting 0.2 ml of emulsion containing 125 μg
of MOG 35–55 peptide (Sigma, Israel) and 1 mg of heat-
killed Mycobacterium tuberculosis extract H37RA (Difco,
Detroit MI, USA) in complete Freund adjuvant (CFA) oil
s.c. into the left flank of C57BL/6 mice. In addition, the
mice received 300 ng of pertussis toxin (List Biological In-
dustries, San Diego CA, USA) intraperitoneally (i.p.) on
days 0 and 2. An additional injection of MOG 35–55 pep-
tide in CFA was delivered into the right flank 7 days later.
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The mice were treated with daily s.c injections of 50 to
200 μg Fn14·TRAIL in a total volume of 200 μL, or vehicle
as control, the starting day after EAE induction varying in
different experiments. All the animals were examined
daily and evaluated for clinical signs of disease.
The first clinical signs appeared on days 10 to 18 post-
immunization. The clinical status of the mice was
graded as follows: 0, without clinical disease; 1, tail
weakness; 2, hind limb weakness sufficient to impair
righting; 3, one plagic limb; 4, paraplegia with forelimb
weakness; 5, quadriplegia; and 6, death.
Ex vivo restimulation and cytokine excretion assays
Pooled spleen and inguinal and mesenterial lymph node
(LN) cells were harvested from MOG35-55 immunized
mice treated with Fn14·TRAIL or vehicle, at different
time points after immunization. For the proliferation as-
says, 2 × 105 cells were cultured in RPMI 1640
supplemented with fetal calf serum (FCS) 5%, 1 mM
sodium pyruvate, nonessential amino acids, 2 mM
L-glutamine, 100 units/ml penicillin, 100 μg/ml strepto-
mycin and 10 μM β-mercaptoethanol in 96 round-
bottom plates, in a total volume of 0.2 ml. The cultures
were stimulated with MOG 35–55 (100 μg/ml) or Conca-
navalin A (ConA; 10 μg/ml, Sigma Aldrich St. Louis
MO, USA). At 48 h, the cultures were pulsed with 1
μCi/well [3H]thymidine (Amersham Pharmacia Biotech,
UK) for 18 h. The cells were then harvested with a semi-
automated automatic harvester onto a glass fiber filter,
and radioactivity was determined by liquid scintillation.
For cytokine assays, harvested cells were cultured in the
same medium, stimulated with MOG35-55 (100 μg/ml)
and incubated for 24 to 72 h. The conditioned media
were collected, and cytokine concentrations were deter-
mined by quantitative ELISA, using paired mAb specific
for the corresponding cytokine, according to the manu-
facturer’s instructions (BD Pharmingen).
Flow cytometry
Surface markers of lymphocytes from pooled LN cells
were evaluated at various time points after EAE induc-
tion. Cells (0.5 × 106 cells/ sample) were immunostained
with the appropriate dilutions of the labeled antibodies
in the presence of Fc blocker (1:300, BD Pharmingen,
USA) and analyzed by FACS scan. The following anti-
bodies were used: PE-conjugated rat anti mouse CD25
(Serotec, UK), anti CD11b (Pharmingen, San Diego CA,
USA), anti-CCR5 (eBioscience) and anti rat IgG2bκ
(Pharmingen, USA); FITC-conjugated rat anti-mouse
CD4 (BioLegend, San diego CA, USA), anti-mouse
CD19, B220, CD3 all from eBioscience, USA, and anti
rat IgG2aκ from Pharmingen, USA. For determination of
the frequency of CD4+CD25+FOXP3+ cells, which were
defined Treg cells, a specific mouse regulatory T-cell
staining kit (eBioscience, San-Diego CA, USA) was used.
The assay was done according to the manufacturer’s
instructions.
Quantitative real-time PCR
The semiquantitative real-time PCR reaction was
performed as described previously [21,22]. The results
for gene expression were normalized to the hypoxantine
phosphoribosyltransferase (HPRT) gene. The primers
used were:
1. HPRT forward TCCTCCTCAGACCGCTTTT





5. RORγt forward: CCCTGGTTCTCATCAATGC
6. RORγt reverse: TCCAAATTGTATTGCAGATGTTC
7. T-bet forward
CAGTTCATTGCAGTGACTGCCTAC
8. T-bet reverse CAAAGTTCTCCCGGAATCCTTT.
Western blot
Upon termination of the experiments, blood was drawn
from the mice and the serum was collected after centri-
fugation. Fn14·TRAIL (100 ng), Fn14 (recombinant
mouse; ALEXIS Biochemicals, San Diego, CA, USA) or
soluble TRAIL (hTRAIL/Apo2L; PeproTech, Rocky Hill,
NJ, USA) were diluted with PBS to a total volume of 20
μL and mixed with Laemmli sample buffer (Bio-Rad) at
a 1:1 ratio with or without betamercaptoethanol, and
heated or not heated for 10 min at 95°C. They were then
loaded onto 10% SDS-PAGE. Following electrophoresis,
the gels were blotted onto nitrocellulose membranes
(Schleicher & Schuell), blocked with 5% milk/PBS, and
probed overnight with either anti-TRAIL (1:000; ALEXIS
biochemicals, San Diego, CA, USA), anti-Fn14 (1:500;
ALEXIS biochemicals) or serum from the different ex-
perimental groups or control mice. After extensive
washing, the blots, were incubated with HRP-conjugated
matching secondary relevant Abs (Bio-Rad, Hercules,
CA, USA) or anti-mouse Abs, and developed with en-
hanced chemiluminescent substrate (Sigma-Aldrich St.
Louis MO, USA) before exposure to X-ray film. The
films were scanned and quantified by ImageMaster
VDS-CL (Amersham Pharmacia Biotech).
Pathology
To test whether Fn14·TRAIL has a toxic effect on the liver
or other organs, on the day of sacrifice, livers, lungs, kid-
neys, guts and brains were harvested from mice in the dif-
ferent experimental groups, or control group, and kept in
formalin. Hematoxylin-eosin stained slides were prepared,
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and sent for blind pathological evaluation. For evaluating
disease involvement of the spinal cord, tissues were sam-
pled on day 20, corresponding to the inflammatory peak
of the disease, before the chronic phase. Anesthetized
mice were sacrificed by total body perfusion with cold 4%
paraformaldehyde in PBS, pH 7.3. Lumbar spinal cords,
where inflammatory foci predominate in our model, were
cut into three coronal segments, fixed in 4% paraformal-
dehyde, dehydrated and embedded in paraffin. Longitu-
dinal sections were cut to include the majority of the
length of the spinal cord, containing both gray and white
matter and stained with Hematoxylin-Eosin. Inflammatory
foci containing at least 20 perivascular mononuclear cells
were counted in each section.
Apoptosis detection
The Jurkat T cell leukemia cell line was used for this
purpose. A total 2 × 105 cells incubated with or without
the indicated proteins for 48 h, were collected, and
stained with annexin V- fluorescein isothiocyanate
(FITC) and propidium iodide (PI), using a MEBCYTO
Apoptosis Kit (MBL, Japan) according to the manufac-
ture protocol. Stained cells (2.5 × 104 cells per sample)
were counted with a BD FACS Calibur flow cytometer;
the results were analyzed using CellQuest software.
Pharmacokinetics
C57BL/6 male mice were selected for this experiment.
Fn14·TRAIL (100 μg) was administered as a single s.c. in-
jection. Blood samples were collected at 0, 1, 4, 8, 24 and
48 h after administration. Serum was analyzed by ELISA
for total Apo2L/TRAIL concentrations, using a TRAIL/
Apo2L ELISA Kit,, DIACLONE, France), according to the
manufacturer’s instructions.
Statistical methods
Group differences were analyzed using Student’s t-test
for two groups or by one way analysis of variance (One
Way ANOVA) for several groups, according to Holm-
Sidak. Differences in disease severity were analyzed using
the Mann–Whitney rank sum test. P <0.05 was consid-
ered significant.
Results
Fn14·TRAIL inhibits early T cell response to MOG35-55
immunization
To assess the influence of Fn14·TRAIL on CNS inflam-
mation, we treated MOG-induced EAE mice from the
day of induction with different doses of Fn14•TRAIL or
vehicle, immediately after immunization. On day 9 after
immunization the mice were sacrificed, and the spleen and
draining lymph-nodes were harvested and weighed. Mice
treated with Fn14·TRAIL had smaller spleens, and fewer
splenocytes. Peripheral blood counts, indicated, however,
that this was specific to the spleen as leukopenia or
lymphopenia were not found following treatment.
In addition, pooled splenocytes or regional lymph-nodes
lymphocytes from treated and nontreated animals were
ex vivo re-stimulated with MOG35-55. Splenocytes and
lymphocytes from mice treated with Fn14·TRAIL prolifer-
ated to a lesser extent when stimulated (Figure 1A). Inter-
estingly, pooled lymphocytes from Fn14·TRAIL treated
mice responded normally to Concanavalin A stimulation.
In opposite, the reactivity of the splenocytes from the
Fn14·TRAIL to treated group to Concanavalin A was sig-
nificantly inhibited to 48% of the activity of vehicle-treated
mice. Furthermore, interferon γ (IFN γ) and IL-17 levels
in the conditioned media of these cells were significantly
reduced (Figure 1B). However, the level of IL-10 did not
differ significantly between the groups, as well as IL-4 (not
shown). Taken together, these findings suggest that
Fn14·TRAIL interferes with the initial T cell response to
MOG35-55. We tested also the effect of Fn14·TRAIL on
the mRNA levels of specific TFs responsible for Th1, Th2
and Th17 lineage differentiation. As can be seen in
Figure 1C, Fn14·TRAIL reduced the level of T-bet expres-
sion by 50% and of ROR-γt by 3.3 fold, similar to the re-
duction in the level of IFN γ and IL-17. In addition, an
increase of 2.5 fold in the expression of GATA-3 the Th2
TF, despite the fact that the IL-10 and IL-4 levels did not
change significantly. Cumulatively, the results support a
role for Fn14·TRAIL in skewing Th lineage development
from Th1 and Th17 to Th2.
We next tested the Fn14·TRAIL effect on immune cell
populations. The phenotype of the splenocytes was char-
acterized by fluorescence-activated cell sorting (FACS)
analysis on day 9. There was no significant difference in
the percentage of CD3, CD4, CD8, CD25, B220, CD19,
CCR5 and CD11b-expressing cells between the placebo-
treated and the Fn14·TRAIL-treated mice. Interestingly,
there was a significant increase in the percentage of
CD4+CD25+FoxP3+ T regulatory cells (Figure 1D).
Fn14•TRAIL treatment decreases the severity of
experimental autoimmune encephalomyelitis
To evaluate the effect of Fn14•TRAIL in vivo, we treated
immunized animals with daily s.c. injections of 25 to 100
μg Fn14·TRAIL, starting on the day of immunization, with
no significant change in disease severity (data not shown).
Interestingly, when treatment was initiated on day 10 after
disease induction and lasted for 14 to 16 days, significant
abrogation of disease severity was detected in mice treated
with 50 to 100 μg of Fn14•TRAIL, (Figure 2A and Table 1).
As treatment with up to 100 μg a day was well tolerated by
the mice, we next tried to shorten treatment duration, using
200 μg of Fn14·TRAIL per mouse per day, and similar re-
sults were obtained. Treatment courses of 7 or even 4 days
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resulted in a significant and long-lasting effect on disease
severity (Figure 2B and Table 1).
Inhibition of central nervous system inflammation by
Fn14•TRAIL
The significant difference in clinical disease score be-
tween Fn14·TRAIL-treated and placebo-treated mice
was consistent with the histological analysis of spinal
cord tissue removed at the peak of the disease (day 20
post-induction). In the placebo-treated group, pro-
nounced perivascular as well as meningeal and white
matter infiltration were observed (Figure 3), whereas
much less inflammation was found in the Fn14·TRAIL-
treated group. A comparison of the number of
inflammatory infiltrates showed a 64% reduction follow-
ing treatment (Figure 3D).
Fn14·TRAIL inhibits Th1 and Th17 responses during the
course of experimental autoimmune encephalomyelitis
To further corroborate the effects of Fn14•TRAIL treat-
ment on the encephlitogenic T cells, when treatment was
initiated on day 10 post-immunization and lasted for 7
days, splenocytes were tested on day 17 upon termination
of treatment and 5 days later (day 22). T cell proliferation
was reduced by 42 and 36% respectively following
Fn14•TRAIL treatment, as was the production of the pro-
inflammatory cytokines INFγ (by 34 and 55% respect-
































































































































Figure 1 Reduced T-cell reactivity in mice treated with Fn14·TRAIL during induction of experimental autoimmune encephalomyelitis
(EAE). Mice were treated with 200 μg/day Fn14·TRAIL subcutaneously (s.c.) for 9 days. Pooled lymphocytes were obtained 9 days post-EAE
induction. (A) Fn14·TRAIL reduced T cell proliferation induced by encephalitogenic Ag MOG35-55. (B) Fn14·TRAIL reduced production of Th1
lineage cytokine IFN γ and Th17 lineage IL-17 with no significant change in Th2 cytokine IL-10. (C) Fn14·TRAIL effect on mRNA levels of Th2
lineage transcription factor GATA-3, Th17 RORγT and T-bet factors. (D) Splenocytes collected on day 9 were immune-stained and analyzed by
fluorescence-activated cell sorting (FACS) for the percentage of CD4+CD25+FoxP3+ cells. (n = 5 in each group). *P <0.05, **P <0.01.
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The percentages indicate the changes in the two time
points tested- day 17 and day 22; post induction. The pro-
duction of the anti-inflammatory cytokine IL-10 was
slightly elevated, but was not statistically significant
(Figure 4).
As can be seen in Figure 4E and 4F, FN14•TRAIL re-
duced the level of ROR-γt by 55 and 30% similar to the
reduction in the level of IL-17. In parallel, an increase in
the expression of GATA-3, was found, supporting the role
of FN14•TRAIL in skewing Th lineage development from
Th1 and Th17 to Th2.
Fn14•TRAIL decreases the number of CCR5-positive T cells
in spleens of treated mice
We tested the possibility that one of the mechanisms by
which Fn14·TRAIL affects inflammation involves alter-
ation of immune cell populations. The phenotype of the
splenocytes was characterized by FACS analysis: There
was no significant difference in the percentage of CD3,
CD4, CD8, CD25, B220, CD19 and CD11b-expressing
cells between the placebo-treated and the Fn14·TRAIL-
treated mice tested on day 9, 17 and 22 post-induction.
Yet, the expression of the murine chemokine receptor
CCR5 was reduced (34, 16 and 19%, respectively). The
reduction was more pronounced for the CD4+CCR5+
cells (53, 52 and 32%, respectively) (Figure 5A,B,C).
Abs against Fn14 or TRAIL not detected
As Fn14·TRAIL is composed of human proteins, we
tested the possibility that the effect obtained might be
due to the antibodies formed against it itself, which
could be inhibitory to the naturally occurring murine
Fn14 or TRAIL. Using immune-blotting, no antibodies
were detected in the serum of treated mice by day 40
when treatment lasted for 16 days. In repeated experi-
ments, we detected a low level of Abs against
Fn14·TRAIL (only at 1:20 titer), but not against Fn14 or
TRAIL, supporting the notion that Abs against TRAIL
or Fn14 are not responsible for the clinical effect of
Fn14·TRAIL.
Furthermore, upon testing the safety of Fn14·TRAIL,
no apparent toxicity could be detected in livers, lungs,
kidneys, gut and hearts of animals treated with up to
200 μg/day These data show that Fn14·TRAIL is not
toxic to mice when injected s.c. for 14 days.
Fn14•TRAIL induces apoptosis in T-cell lines
We tested whether Fn14·TRAIL is capable of inducing
apoptosis in T cells. For this purpose, Jurkat T cell line
cells were incubated with Fn14•TRAIL for 24 to 48 h and
apoptosis was detected by flow-cytometry. At 24 h 30% of
the cells, and at 48 h up to 60% of the cells, were apop-
totic (Figure 6), supporting the notion that Fn14•TRAIL



















































Figure 2 Treatment with Fn14·TRAIL ameliorated the clinical
course of experimental autoimmune encephalomyelitis (EAE).
(A) Daily treatment with Fn14·TRAIL 25–100 μg/day subcutaneously
(s.c.) for 14 days from day 10 post-induction. Doses of 50 and 100
μg/day significantly ameliorated the clinical score of EAE (see also
Table 1). (B). Shorter treatment duration with Fn14·TRAIL 200 μg/day
for 7 or 4 days, also ameliorated the clinical score of EAE (see also
Table 1).
Table 1 Amelioration of experimental autoimmune
encephalomyelitis (EAE) by Fn14·TRAIL
Treatment Disease mean severity
Vehicle 2.4 ± 0.2
Fn14·TRAIL 25 μg/day (14-day treatment) 2.3 ± 0.2
Fn14·TRAIL 50 μg/day (14-day treatment) 1.6 ± 0.1*
Fn14·TRAIL 100 μg/day (14-day treatment) 1.5 ± 0.1*
Fn14·TRAIL 200 μg/day (14-day treatment) 1.2 ± 0.1*
Fn14·TRAIL 200 μg/day (7-day treatment) 1.4 ± 0.3*
Fn14·TRAIL 200 μg/day (4-day treatment) 1.2 ± 0.3*
The data are expressed as mean disease score ± SE, in 21 control-vehicle
treated mice, and in 10 mice in each treatment group. Treatment started from
day 10 post-induction and lasted for the time periods indicated. *P <0.05
versus control.
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When Jurkat cells were cocultured with Fn14·TRAIL
and TWEAK, the natural ligand of Fn14, 100% of the
cells underwent apoptosis. Tweak itself had no effect on
these cells.
It should be noted that the inhibitory effect of
Fn14•TRAIL in vitro on mice MOG35-55 or ConA stimu-
lated splenocytes was evident only when a very high dose of
Fn14•TRAIL was used. At concentrations of 3000 ng/ml of
Fn14•TRAIL, ConA-induced splenocyte proliferation was
inhibited by 24%, and MOG35-55 induced proliferation was
inhibited by 23%. At concentration of 1500 ng/ml,
Fn14•TRAIL’s presence induced only 10% inhibition of
ConA-induced splenocyte proliferation, and 25% of the re-
sponse to MOG35-55 stimulation.
Discussion
In the present study we demonstrate that Fn14·TRAIL
protein significantly downregulates EAE. Fn14•TRAIL
could affect several stages in the cascade of events leading
to CNS inflammation. It is conceivable that it can act
already in the early stages of the disease by inhibiting the
reactivity of encephalitogenic T cells. When administered
by daily injection from day 10 post-disease induction,
Fn14·TRAIL significantly attenuated clinical disease sever-
ity, as well as the number of CNS inflammatory foci.
MS and EAE are autoimmune inflammatory diseases
in which cytokines are extensively involved. Th1 and
Th17 cytokines, which play a role in the induction of
CNS inflammation and demyelination and in the patho-
genesis of EAE and MS [23,24], were markedly reduced
by Fn14·TRAIL.
Upon studying the effects of Fn14·TRAIL on specific
cell types, we found a decreased number of CCR5+ cells,
particularly CD4+CCR5+. CCR5 is expressed mainly on
T cells and is associated with a Th1 immune response
[25,26].
Fn14·TRAIL affects both Th1 and Th17 cells, the two
believed to take an active part in the evolvement of EAE.
This was the case when Fn14·TRAIL was given during
the priming phase after immunization and splenocytes
were harvested on day 9 post-immunization and also
when Fn14·TRAIL was given from day 10 for 7 days on
day 17 or 22 post-induction. This is in agreement with
previous work describing the inhibition of EAE by
in vivo expression of Fn14•TRAIL [20]. In our study,
however, we treated the animals for a much shorter time,
with a very significant inhibitory effect.
Fn14·TRAIL has two potentially active domains. The
first, Fn14, is the natural receptor for TWEAK, which
has been described as playing an enhancing role in EAE
[13,18,27]. Blocking Fn14: TWEAK has been suggested
to have a beneficial effect in the treatment of inflamma-
tory diseases [28,29], EAE specifically [19]. This sugges-






























Figure 3 Treatment with Fn14·TRAIL improves central nervous system (CNS) inflammation and reduces experimental autoimmune
encephalomyelitis (EAE) lesions. Spinal cords of mice from control and Fn14·TRAIL groups were removed at disease peak (day 20 post-
induction). Hematoxylin-eosin staining revealed marked perivascular, meningeal and white matter infiltration in EAE mice treated with vehicle ((A)
10X magnifications and (B) 40X magnification of one perivascular inflammatory lesion). Following treatment with Fn14·TRAIL 200 μg/day for
7 days, a marked and significant reduction in inflammation was observed (C, D) *P <0.05.
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secretion of pro-inflammatory cytokines such as IL-6
and MCP-1 [30], but mainly on the finding that blocking
of the TWEAK:Fn14 interaction reduced disease severity
in EAE [19,27]. We observed that Fn14·TRAIL lowered
disease severity only when given from day 10 after MOG
immunization. Treatment of the mice from day 1 did
not yield the same effect. This is in agreement with the
previous findings of Desplat-Jego et al. who showed that
blocking anti-TWEAK Abs given from day 9 after MOG
immunization significantly inhibited clinical symptoms
of EAE in mice, and decreased the number of CNS in-
flammatory foci [27]. Of note, anti-TWEAK Abs did not
affect the ex vivo T cell response to MOG35-55 re-
challenge when given on day 9 from immunization.
Fn14·TRAIL did inhibit the T-cell response to ex vivo
restimulation, highlighting the difference between the
two agents and suggesting that more than one mechan-
ism is involved in Fn14·TRAIL’s inhibitory effect. Im-
portantly, although Fn14·TRAIL has a short half-life
compared with that of antibodies, its effect was as long
lasting as that of the Abs administered. This might be
due to its influence on pathogenic T cell migration to
the CNS. Such an effect has been suggested also by
Desplat-Jego et al. [18,27] and by Razmara et al. [20].
The other domain of Fn14·TRAIL is the extracellular
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Figure 4 Treatment with Fn14·TRAIL suppresses T-cell reactivity during various stages of experimental autoimmune encephalomyelitis
(EAE) course. (A) T-cell proliferation in response to encephalitogenic peptide MOG35-55 was assessed upon termination of treatment (day 17
post-induction) and 5 days later (day 22). Animals received 200 μg/day for 7 days from day 10 post- EAE induction. (B – D) Fn14·TRAIL reduced
production of Th1 and Th17 cytokines IFNγ and IL-17, with no change in production of Th2 cytokine IL-10. ( E-F) Fn14·TRAIL effects were
determined on mRNA levels of the Th2 lineage-specific transcription factor (TF) GATA-3, with increased expression (E), and a reduction in Th17 TF
RORγT (F). *P <0.05, **P <0.01
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of TRAIL in the amelioration of EAE severity. Soluble
TRAIL has been shown to suppress the disease in mice
[31] and blocking of TRAIL, especially when given just be-
fore the first clinical signs of the disease appeared, resulted
in significant augmentation of symptoms. [6,31]. Moreover,
when EAE was induced by MOG-expressing dendritic cells
(DCs) disease severity was hampered if these DCs also
expressed TRAIL [7]. Interestingly, other studies, using
adoptive transfer of TRAIL −/− lymphocytes, have shown
that TRAIL has a neurodegenerative effect on CNS-
infiltrating lymphocytes inducing demyelination, and that
selective blocking of TRAIL’s activity by intracisternal ad-
ministration of DR5:Fc fusion protein, successfully inhibited
the clinical and pathological signs of EAE [32]. Intriguingly,
Fn14•TRAIL can be anchored to TWEAK- expressing DCs
and present TRAIL to TRAIL-receptor bearing cells, such
as activated T cells, thus mimicking the genetically
engineered TRAIL-expressing DCs. Also, as it has been
shown to interfere with BBB permeability, these DCs will
act mainly in the periphery and not in the CNS [20].
The ability of Fn14•TRAIL to inhibit murine sple-
nocytes’ response to stimulation, either antigen specific or
mitogenic, could be explained by its ability to induce
apoptosis through the TRAIL moiety or to inhibit prolifer-
ation (by interfering with the TWEAK: Fn14 axis). The
finding that Fn14•TRAIL is capable of inducing apoptosis
in the Jurkat T cell line supports the first assumption.
An interesting finding from our experiments is that
Fn14·TRAIL inhibited clinical signs of disease only when
given closer to time of disease onset, and had no signifi-
cant effect when given from time of immunization, as was
described for blocking TWEAK or TRAIL [27]. There are
several possible explanations for this phenomenon. It may






































































Figure 5 Fn14·TRAIL alters subpopulations of CCR5+
expressing cells, particularly CCR5+Tcells during different
stages of experimental autoimmune encephalomyelitis (EAE).
(A) Splenocytes derived from vehicle and Fn14·TRAIL- treated
(200 μg/day) EAE mice, from the day of induction were analyzed for
expression of surface markers by fluorescence-activated cell sorting
(FACS) analysis as described in Materials and Methods. Expression of
CCR5 alone and together with CD4+ for the total splenocytes is
shown and is based on the number of cells expressing each marker.
(B –C) Splenocytes removed on day 17 or day 22 post-induction
from mice were treated with 200 μg/day from day 10 post-
induction for 7 days, *P <0.05.
Fn14-TRAIL (ng/ml)



















Figure 6 Effect of Fn14·TRAIL in vitro on Jurkat cells. Jurkat cells
were exposed to two concentrations of Fn14·TRAIL for 24 and 48 h,
as well as to a/FAS as positive control. Apoptosis was measured
using an Annexin-PI kit, as described in Materials and Methods. The
extent of apoptosis induced by Fn14·TRAIL after 24 and 48 h was 2.5
and 3.5 fold, respectively in the presence of 300 ng/ml Fn14·TRAIL.
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changing the balance between effector and regulatory cells
in a way that facilitates the appearance of clinical disease,
and that late treatment affects the effector cells, while par-
tially sparing the regulatory/inhibitory cells. We did not
find any difference in the prevalence of total CD4, CD8 or
CD25 positive cells in the spleen, but did find a significant
decrease in CCR5-expressing CD4 cells. CCR5 has been
shown to be essential for T-cell recruitment to the inflam-
matory site in EAE, and specific targeting of CCR5-
expressing cells was shown to be helpful in treating EAE
mice [33,34]. Another possibility could be the develop-
ment of blocking Abs against the human fusion protein
given to the mice, resulting in the prevention of its inhibi-
tory effect from day 10 and on. Although we did not de-
tect anti-TRAIL or anti-Fn14 Abs in the sera of treated
mice, this possibility cannot be excluded.
Conclusions
In summary, Fn14·TRAIL proved to be very effective in
inhibiting the clinical course of EAE, even when given
for a short time from day 10 of induction, and is corre-
lated to the diminished inflammatory response detected
in the CNS. Importantly, no signs of toxicity were found
in the treated mice. Fn14•TRAIL’s action involves inhib-
ition of the T cell response, particularly of Th1 and Th17,
and a decreased number of CCR5+CD4+ cells. Cumula-
tively, our findings support the immunomodulatory poten-
tial of FN14•TRAIL in the treatment of MS and other
autoimmune diseases.
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